Cellectis Analyst Ratings
Cellectis Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 494.59% | Oppenheimer | → $11 | Reiterates | Outperform → Outperform |
| 08/07/2023 | 224.32% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 04/05/2023 | 764.86% | Citigroup | $24 → $16 | Maintains | Buy |
| 03/13/2023 | 602.7% | Oppenheimer | $16 → $13 | Maintains | Outperform |
| 03/13/2023 | 224.32% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 01/19/2023 | 224.32% | JMP Securities | $11 → $6 | Maintains | Market Outperform |
| 05/24/2022 | 8.11% | Goldman Sachs | $3 → $2 | Maintains | Sell |
| 05/18/2022 | — | Baird | Upgrades | Neutral → Outperform | |
| 05/13/2022 | 278.38% | Barclays | $9 → $7 | Maintains | Overweight |
| 01/06/2022 | 764.86% | Wells Fargo | → $16 | Downgrades | Overweight → Equal-Weight |
| 11/30/2021 | 981.08% | JMP Securities | → $20 | Initiates Coverage On | → Market Outperform |
| 10/08/2021 | 440.54% | Baird | $39 → $10 | Downgrades | Outperform → Neutral |
| 04/28/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 03/16/2021 | 2008.11% | Baird | $23 → $39 | Upgrades | Neutral → Outperform |
| 10/15/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 08/19/2020 | 1629.73% | Citigroup | $15 → $32 | Upgrades | Neutral → Buy |
| 07/07/2020 | 1035.14% | Baird | $28 → $21 | Maintains | Outperform |
| 03/06/2020 | 494.59% | Goldman Sachs | $15 → $11 | Downgrades | Neutral → Sell |
| 02/19/2020 | 2008.11% | BTIG | $37 → $39 | Maintains | Buy |
| 08/09/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 05/24/2019 | — | Citigroup | Assumes | → Neutral | |
| 03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/19/2018 | 1251.35% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/08 | 494.59% | 奧本海默 | →$11 | 重申 | 跑贏→跑贏大盤 |
| 08/07/2023 | 224.32% | JMP證券 | →$6 | 重申 | 市場表現優於→市場表現 |
| 04/05/2023 | 764.86% | 花旗集團 | $24→$16 | 維護 | 買 |
| 03/13/2023 | 602.7% | 奧本海默 | $16→$13 | 維護 | 跑贏大盤 |
| 03/13/2023 | 224.32% | JMP證券 | →$6 | 重申 | →市場跑贏大盤 |
| 2023年1月19日 | 224.32% | JMP證券 | $11→$6 | 維護 | 市場表現強於大盤 |
| 2022年05月24日 | 8.11% | 高盛 | $3→$2 | 維護 | 賣 |
| 2022/05/18 | - | 貝爾德 | 升級 | 中性→表現優異 | |
| 2022年05月13日 | 278.38% | 巴克萊 | $9→$7 | 維護 | 超重 |
| 01/06/2022 | 764.86% | 富國銀行 | →$16 | 評級下調 | 超重→等重 |
| 2021年11月30日 | 981.08% | JMP證券 | →$20 | 開始承保 | →市場跑贏大盤 |
| 10/08/2021 | 440.54% | 貝爾德 | $39→$10 | 評級下調 | 跑贏→中性 |
| 04/28/2021 | - | 古根海姆 | 評級下調 | 購買→中性 | |
| 03/16/2021 | 2008.11% | 貝爾德 | $23→$39 | 升級 | 中性→表現優異 |
| 10/15/2020 | - | 貝爾德 | 評級下調 | 跑贏→中性 | |
| 2020年08月19日 | 1629.73% | 花旗集團 | $15→$32 | 升級 | 中性→購買 |
| 07/07/2020 | 1035.14% | 貝爾德 | $28→$21 | 維護 | 跑贏大盤 |
| 03/06/2020 | 494.59% | 高盛 | $15→$11 | 評級下調 | 中性→銷售 |
| 02/19/2020 | 2008.11% | BTIG | $37→$39 | 維護 | 買 |
| 2019年08月09日 | - | BTIG | 開始承保 | →購買 | |
| 2019年05月24日 | - | 花旗集團 | 假設 | →中性 | |
| 2019/03/14 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 2018年12月19日 | 1251.35% | 高盛 | →$25 | 開始承保 | →中性 |
What is the target price for Cellectis (CLLS)?
Cellectis(CLLS)的目標價是多少？
The latest price target for Cellectis (NASDAQ: CLLS) was reported by Oppenheimer on August 8, 2023. The analyst firm set a price target for $11.00 expecting CLLS to rise to within 12 months (a possible 494.59% upside). 6 analyst firms have reported ratings in the last year.
奧本海默於2023年8月8日報道了Cellectis(納斯達克：CLLS)的最新目標價。這家分析公司將目標價定為11美元，預計CLL將在12個月內升至(可能上漲494.59%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Cellectis (CLLS)?
Cellectis(CLLS)的最新分析師評級是多少？
The latest analyst rating for Cellectis (NASDAQ: CLLS) was provided by Oppenheimer, and Cellectis reiterated their outperform rating.
Cellectis(納斯達克代碼：CLLS)的最新分析師評級由奧本海默提供，Cellectis重申其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Cellectis (CLLS)?
Cellectis(CLLS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectis was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Cellectis的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Cellectis的上一次評級是在2023年8月8日提交的，所以你應該預計下一次評級將在2024年8月8日左右提供。
Is the Analyst Rating Cellectis (CLLS) correct?
分析師評級Cellectis(CLLS)正確嗎？
While ratings are subjective and will change, the latest Cellectis (CLLS) rating was a reiterated with a price target of $0.00 to $11.00. The current price Cellectis (CLLS) is trading at is $1.85, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Cellectis(CLLS)評級被重申，目標價在0.00美元至11.00美元之間。Cellectis(CLLS)目前的交易價格為1.85美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。